IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to SobiZacks Investment Research • 03/27/25
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.Business Wire • 03/26/25
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?Zacks Investment Research • 03/21/25
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia VeraBusiness Wire • 03/11/25
Ionis and Ono announce global license agreement for sapablursen in polycythemia veraBusiness Wire • 03/11/25
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathyBusiness Wire • 03/10/25
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in FocusZacks Investment Research • 02/20/25
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease controlBusiness Wire • 02/20/25
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 SalesBenzinga • 02/19/25
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/12/25
Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034GlobeNewsWire • 01/15/25
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentumPRNewsWire • 01/13/25
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In BloodBenzinga • 12/20/24
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietPRNewsWire • 12/19/24
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%Zacks Investment Research • 12/11/24